Elan is a bio/pharmaceutical company with roots in Ireland and the US. It has 2 primary foci: biologic treatments for neurologic indications and drug delivery.
They currently have several sources of revenue:
* Drug delivery manufacturing and R&D contract services
* Nanotechnology drug delivery licensing and manufacturing services (among major drugs approved are Tricor (5%), and Magace... major drugs in progress include Palperdone Palmitate in P3)
* Older hospital drugs that will gradually come off patent
* Tysabri - a monoclonal antibody product approved by the FDA and EMEA and pending approval by EMEA for treatment of Crohns Disease.
* Prialt, an intrathecally delivered synthetic toxin for relieving pain otherwise untreatable by morphine (EU marketing/sales rights sold to Eisai 2/2006)
In R&D are:
* AAB-001 mAb for Alzheimer's Disease (P2)
* AAB-002 mAb for Alzheimer's Disease (expected IND 2006)
* AAC-001 immunoconjugate for Alzheimer's Disease (P1)
* beta secretase program for Alzheimer's Disease
* gamma secretase program for Alzheimer's Disease
* right to 50% of Eli Lilly's gamma secretase AD program
* publicly unnamed mAb for treatment of Parkinson's Disease
* ELND-001 and ELND-002: anti-VLA4 small molecules for RA and MS respectively, going into clinic in 2006
* PD mAb targeting Lewy Bodies will go into the clinic after Tysabri is re-launched.
* Some 3 dozen reformulated and newly formulated nanotech products in P1, P2 and P3.
This thread is now moderated: please be civil and keep the discussion on topic (about Elan.) Shorts and Longs are both welcome with the caveat that cheerleading and slamming without reasoning and sources to back them up are not welcome. |
